Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Letter Oncology

Immune responses following third COVID-19 vaccination are reduced in patients with hematological compared to patients with solid cancer

Annika Fendler et al.

CANCER CELL (2022)

Add to Collection

Letter Medicine, General & Internal

Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer

Annika Fendler et al.

LANCET (2022)

Add to Collection

Editorial Material Oncology

Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

Hagai Ligumsky et al.

LANCET ONCOLOGY (2022)

Add to Collection

Article Immunology

Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients

Corine H. GeurtsvanKessel et al.

Summary: This study demonstrates that vaccinated individuals retain T cell immunity to the SARS-CoV-2 Omicron variant, despite low levels of neutralizing antibodies. Booster vaccinations can partially restore cross-neutralization of the Omicron variant.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Article Oncology

COVID-19 vaccination and breakthrough infections in patients with cancer

A. L. Schmidt et al.

Summary: This study analyzes the clinical features of cancer patients who develop symptomatic COVID-19 after vaccination. It finds that these patients often have comorbidities and can experience severe and even lethal infections. Hematologic malignancy patients are over-represented among the vaccinated cancer patients who develop symptomatic COVID-19. Therefore, while vaccination remains crucial in protecting vulnerable populations, including cancer patients, those who develop breakthrough infections despite full vaccination still face the risk of severe outcomes.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Annika Fendler et al.

Summary: The efficacy and immunogenicity of COVID-19 vaccines in cancer patients are uncertain due to their exclusion from pivotal clinical trials. In this Review, the current knowledge on vaccine efficacy and immune responses in cancer patients is summarized, highlighting key factors that may affect vaccine efficacy in this population.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Sjoukje F. Oosting et al.

Summary: This study aimed to evaluate the immunogenicity and safety of the mRNA-1273 COVID-19 vaccine for patients with solid tumours receiving systemic cancer treatment. The majority of patients developed an adequate antibody response after two vaccinations, indicating the vaccine is safe in these patients. Some patients with an inadequate response may benefit from a third vaccination.

LANCET ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Einav G. Levin et al.

Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

M. Peeters et al.

Summary: The study found that cancer patients receiving COVID-19 vaccination experienced mostly mild to moderate local and systemic adverse events, with more frequent local adverse events following the booster dose. Additionally, immunized cancer patients had delayed and diminished antibody responses, particularly in those receiving chemotherapy or rituximab treatments.

ESMO OPEN (2021)

Add to Collection

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Related references

Export Citation

Share Paper